Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 4 | 2024 | 1553 | 1.500 |
Why?
|
| Radiation Pneumonitis | 3 | 2016 | 103 | 1.100 |
Why?
|
| Radiosurgery | 6 | 2017 | 1335 | 1.030 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2024 | 24 | 0.940 |
Why?
|
| Prostaglandins I | 1 | 2020 | 13 | 0.740 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2020 | 103 | 0.680 |
Why?
|
| Mediastinum | 1 | 2021 | 265 | 0.680 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2019 | 140 | 0.560 |
Why?
|
| Esophagitis | 1 | 2017 | 164 | 0.540 |
Why?
|
| Probability | 1 | 2018 | 2477 | 0.430 |
Why?
|
| Pulmonary Embolism | 3 | 2024 | 2515 | 0.410 |
Why?
|
| Vascular Diseases | 1 | 2021 | 1177 | 0.410 |
Why?
|
| Lung Neoplasms | 6 | 2017 | 13173 | 0.370 |
Why?
|
| Lung Diseases | 1 | 2021 | 1899 | 0.360 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1180 | 0.350 |
Why?
|
| Hospitalization | 2 | 2019 | 10628 | 0.330 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 1278 | 0.330 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1515 | 0.310 |
Why?
|
| Hospital Mortality | 2 | 2019 | 5370 | 0.310 |
Why?
|
| Heart | 1 | 2021 | 4374 | 0.290 |
Why?
|
| Radiotherapy Dosage | 5 | 2017 | 2906 | 0.290 |
Why?
|
| Heart Diseases | 1 | 2019 | 2790 | 0.280 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 3509 | 0.270 |
Why?
|
| Hemorrhage | 1 | 2018 | 3570 | 0.270 |
Why?
|
| Lung | 2 | 2024 | 9899 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 5215 | 0.250 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2024 | 271 | 0.210 |
Why?
|
| Epoprostenol | 1 | 2020 | 249 | 0.170 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 1926 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2021 | 615 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 873 | 0.130 |
Why?
|
| Lung Volume Measurements | 1 | 2016 | 375 | 0.120 |
Why?
|
| Aged | 11 | 2024 | 166705 | 0.120 |
Why?
|
| Hemodynamics | 1 | 2024 | 4173 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2016 | 1875 | 0.110 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 881 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2024 | 79160 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 2037 | 0.090 |
Why?
|
| Humans | 16 | 2024 | 752810 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2021 | 3803 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2019 | 1911 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2024 | 8468 | 0.080 |
Why?
|
| Risk | 1 | 2019 | 9613 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2560 | 0.070 |
Why?
|
| Male | 10 | 2024 | 355160 | 0.070 |
Why?
|
| Female | 10 | 2024 | 386339 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3146 | 0.060 |
Why?
|
| Sepsis | 1 | 2019 | 2590 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 1822 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15695 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10475 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 39089 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 11067 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2024 | 23785 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10200 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2016 | 9701 | 0.060 |
Why?
|
| Middle Aged | 6 | 2024 | 217250 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12138 | 0.050 |
Why?
|
| Acute Disease | 2 | 2024 | 7217 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15505 | 0.050 |
Why?
|
| Logistic Models | 1 | 2016 | 13277 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 29369 | 0.040 |
Why?
|
| Risk Factors | 2 | 2016 | 73418 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20350 | 0.040 |
Why?
|
| Time Factors | 1 | 2019 | 39885 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 25540 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9207 | 0.030 |
Why?
|
| United States | 3 | 2021 | 71434 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 1669 | 0.030 |
Why?
|
| Survival | 1 | 2016 | 161 | 0.030 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 732 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2016 | 321 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12751 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2015 | 148 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 217168 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 53833 | 0.020 |
Why?
|
| Propensity Score | 1 | 2016 | 1872 | 0.020 |
Why?
|
| Echocardiography | 1 | 2021 | 4949 | 0.020 |
Why?
|
| Dyspnea | 1 | 2015 | 1347 | 0.020 |
Why?
|
| Linear Models | 1 | 2016 | 5858 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6503 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 10187 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12455 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14601 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 58347 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 64288 | 0.010 |
Why?
|
Concepts
(86)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(15)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_